Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.

"CONFLICT OF INTEREST C.M. Boesjes is a speaker for Abbvie and Eli Lilly. D.S. Bakker is a speaker for Sanofi Genzyme and Leo Pharma. F. van Wijk is a speaker and/or consultant for Janssen, Johnson&Johnson, and Takeda and has received grants from Regeneron, Leo Pharma, Sanofi Genzyme, BMS, Galapagos, and Takeda. M.S. de Bruin‐Weller is a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Aslan, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi Genzyme. M. de Graaf is a consultant, advisory board member, and/or speaker for Sanofi Genzyme and Regeneron and Leo Pharma, and is an advisory board member for Eli Lilly. M.L.A. Schuttelaar is a consultant, advisory board member, and/or speaker for AbbVie, Pfizer, Leo Pharma, Sanofi Genzyme, Eli Lilly and Galderma. All other authors have no conflicts of interest to declare."

"FUNDING INFORMATION The BioDay registry is sponsored by Sanofi/Regeneron, Abbvie, Leo Pharma, Pfizer and Eli Lilly. They have no influence on the collection, analysis and interpretation of the data."